Posted 14 September, 2023

Orthofix Medical Inc. appointed Catherine M. Burzik as new CEO

Nasdaq:OFIX appointed new Chief Executive Officer Catherine M. Burzik in a 8-K filed on 14 September, 2023.

  Also on September 11, 2023, the Board appointed Catherine M. Burzik, the current Chair of the Board, as Interim Chief Executive Officer, effectively immediately.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Orthofix Medical Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.
Market Cap
View Company Details
Relevant filing section
Item 5.02 
Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers. 

On September 11, 2023, the Board of Directors (the "Board") of Orthofix Medical Inc. ("Orthofix" or the "Company") terminated the employment of Keith Valentine, the Company's Chief Executive Officer, John Bostjancic, the Company's Chief Financial Officer and Patrick Keran, the Company's Chief Legal Officer. The Board's decision follows an investigation conducted by independent outside legal counsel and directed and overseen by the Company's independent directors. As a result of the investigation, the Board determined that each of these executives engaged in repeated inappropriate and offensive conduct that violated multiple code of conduct requirements and was inconsistent with the Company's values and culture. The Company has notified Mr. Valentine, Mr. Bostjancic and Mr. Keran that such terminations have been made for "Cause," as defined in applicable employment-related agreements (including each executive's respective Change in Control and Severance Agreement, dated June 19, 2023). As a result, the Company does not believe it is required to make any further payments to the terminated executives, other than payment of salary for the days worked in the current pay period through September 12, 2023 and unused paid time off. In connection with Mr. Valentine's termination, the Board has asked him to resign from the Board. 

Also on September 11, 2023, the Board appointed Catherine M. Burzik, the current Chair of the Board, as Interim Chief Executive Officer, effectively immediately. The Board also appointed Geoffrey C. Gillespie as Interim Chief Financial Officer and Puja Leekha as Interim Chief Legal Officer, each effective immediately. 

Ms. Burzik, age 72, was appointed Chair of the Board in June 2023. She previously served as the Chair of the Orthofix Board from 2021-2022 before assuming the position of Lead Independent Director in January 2023. She previously served as President and Chief Executive Officer of Kinetic Concepts, Inc., a global medical device company, from 2006 until the company's sale in 2011. Prior to that, Ms. Burzik served as President of Applied Biosystems Group and held senior executive positions at Eastman Kodak and Johnson & Johnson, including Chief Executive Officer and President of Kodak Health Imaging Systems and President of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company. Since 2013, Ms. Burzik has served as a member of the Board of Directors of Becton, Dickinson and Company, where she currently chairs the Quality and Regulatory Compliance Committee and serves on the Corporate Governance and Nominating Committee. Ms. Burzik serves as Chairman Emeritus of StemBioSys, Inc. and Chairman Emeritus of the American College of Wound Healing and Tissue Repair. Ms. Burzik previously served on the Board of Directors for the San Antonio Branch of the Dallas Federal Reserve Board, Allscripts, Inc., Bausch & Lomb, Cordis Corporation and AdvaMed. Additionally, Ms. Burzik previously served as a member of the Board of Directors of Haemonetics Corporation from 2016 to 2023, where she chaired the Technology Committee and served on the Audit Committee. 

Mr. Gillespie, age 52, has served as the Vice President, Corporate Controller of Orthofix since May 2021, and previously served as Senior Director of U.S. Accounting and Consolidations at the Company from August 2013 until his promotion in 2021. Prior to joining Orthofix, Mr. Gillespie held various financial reporting management roles at Flowserve, and prior to that, at Deloitte for over seven years. Mr. Gillespie holds a Bachelor of Applied Science in Accounting and Finance from the University of Utah and a Masters of Business Administration in Finance from Baylor University. 

Ms. Leekha, age 47, joined Orthofix in 2023 as Senior Vice President, Chief Ethics and Compliance Officer. In this role she is responsible for all aspects of the Company's compliance program and policies. Prior to joining Orthofix, Ms. Leekha spent more than 18 years in a variety of legal and compliance roles within the medical device and pharmaceutical industries, including with Stryker, a global medical technology company, and as a litigator with the law firm now known as Faegre Drinker Biddle & Reath LLP defending medical device and pharmaceutical companies in product liability actions. Most recently, from June 2018 until joining Orthofix, she served as Vice President, Chief Compliance Officer, and Corporate Counsel, North America for Lundbeck, a global biopharmaceutical company committed to researching, developing and delivering transformative therapies for brain diseases. At Lundbeck, Ms. Leekha reported directly to Lundbeck's President of North America and was responsible for the leadership, development, implementation and management of the company's Compliance Program. She was also responsible for the negotiation, implementation and execution of Lundbeck's Corporate Integrity Agreement with the Office of the Inspector General. Ms. Leekha was a member of Lundbeck's North America Senior Leadership Team, Lundbeck's Global Leadership Team, and Lundbeck's Global Legal Leadership Team. She was the Chair of the Compliance Committee and served as the Executive Sponsor for Lundbeck's Diversity, Equity & Inclusion Council. 

The Company anticipates that the Compensation and Talent Development Committee of the Board will review compensation arrangements for the newly appointed executives in the near-term.